Edwards Lifesciences Co. (NYSE:EW) Receives $78.65 Average Price Target from Analysts

Shares of Edwards Lifesciences Co. (NYSE:EW) have been assigned an average rating of “Hold” from the twenty-six analysts that are covering the company, MarketBeat reports. Fifteen investment analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $79.40.

Several equities analysts recently issued reports on the company. Barclays boosted their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, December 2nd. Piper Sandler lowered their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Wells Fargo & Company cut their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Truist Financial reiterated a “hold” rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Finally, JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a report on Friday, October 25th.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,262,521.36. This trade represents a 9.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the company’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,500 shares of company stock worth $2,508,350 over the last quarter. 1.29% of the stock is currently owned by insiders.

Institutional Trading of Edwards Lifesciences

Several hedge funds and other institutional investors have recently modified their holdings of EW. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences in the 3rd quarter valued at $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences in the third quarter valued at about $32,000. Avior Wealth Management LLC grew its stake in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. Peoples Bank KS bought a new position in Edwards Lifesciences during the third quarter worth about $40,000. Finally, JFS Wealth Advisors LLC raised its stake in Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.3 %

Shares of NYSE EW opened at $74.15 on Friday. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The stock has a market cap of $43.73 billion, a price-to-earnings ratio of 10.70, a P/E/G ratio of 3.63 and a beta of 1.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company’s fifty day moving average is $69.72 and its 200-day moving average is $73.71.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the company posted $0.59 earnings per share. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. Equities research analysts predict that Edwards Lifesciences will post 2.56 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.